Kairos Pharma, LTD. — Director's Dealing 2025

Apr 30, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2024-12-10

Reporting Person: Singhvi Rahul (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	30120	Direct

Footnotes

F1: The Reporting Person started serving as an independent director of the board of directors of the Company as of December 10, 2024. On the same date, the Company issued 30,120 restricted stock units ("RSUs") to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 30,120 RSUs are scheduled to vest in one third increments on each of 12/10/2025, 12/10/2026 and 12/10/2027. Accordingly, none of the RSUs have vested as of the date hereof.